Tag: ZLCS

LTCHD, EDXC, PVEN, FB & Extended Watchlist

mCig, Inc. LTCHD

We put LTCHD up on yesterday afternoon’s Extended Watchlist, and are entering it into the discussion this morning as a new play on our marijuana-related stock radar. The company has recently transitioned to a new name, from Lifetech Industries to the current mCig. Along with that change, the company effected a 10-for-1 forward split.

For people who already owned shares prior to the restructuring, those shares were subject to a routine hold, which can take 3-5 days for the position to become free-trading. So we are on the lookout for a pullback this mid-week as that occurs, and people attempt to lock in profits by selling their shares into the market.

From there, we’ll be on the lookout for a bottom, and subsequent bounce.

The company falls under the marijuana stock category, as they are preparing for the rollout of their first mCig product within the next month. The company will be looking to capitalize on the legalization of marijuana in two states, as well as the growing popularity of “vapor pens” which vaporize cannabis concentrates for consumption.

BELLEVUE, WA, Aug 28, 2013 (Marketwired via COMTEX) — Lifetech Industries, Inc. (OTCBB: LTCHD), announces today that it has changed its name to mCig, Inc. and completed a forward stock split on a 10-for-1 basis.

On August 2, 2013, the Company’s Certificate of Incorporation was amended and restated to effect the name change and the forward stock split. The name change is part of an initiative led by incoming CEO Paul Rosenberg to reposition the company and its technology by launching a new consumer product, the mCig — a purpose built loose leaf eCig that will be launched next month.

mCig’s CEO, Paul Rosenberg, commented: “With the name change complete we can now focus on the next chapter of our business development targeting two long-term secular trends by developing consumer products that are exciting and disruptive. We will be updating our shareholders shortly with more information on our first product the mCig which will be launched in Q3 2013.”

The name change and the forward stock split were also approved by the Financial Industry Regulatory Authority (“FINRA”). The name change and forward split will be effective for trading purposes on the open of business on Thursday August 29, 2013. The new symbol will be (LTCHD) for 20 business days until September 27, 2013 when the symbol will change to (MCIG).

ENDEXX Corp. EDXC

EDXC is another medical marijuana play that we’ve been covering for quite some time. It also appeared in Friday’s report that revisited our interest in many cannabis stocks. Since that time, EDXC has traded from a low of .055 (Friday) to yesterday’s high of .097. That works out to a two-session move of 76%

Congrats to anyone who was able to take advantage of that timely alert, and be sure to check out that report containing all of our marijuana interests, as the entire sector was given a morale boost via last week’s US Department of Justice announcement that the federal government would not be interfering in individual states rights to make marijuana available to their citizens for both medical and recreational use.


Press Ventures, Inc. PVEN

PVEN has experienced an abnormal burst in volume over the past week or so, and yesterday’s volume exceeded the three days’ prior combined. Given that the stock wasn’t really trading up to that point, we have reason to suspect that PVEN could be the subject of an upcoming promotion. This out-of-the-blue volume explosion could be a result of front-loading, and so we are placing this stock on watch for any major price movements that could occur.

We also exercise the utmost caution when dealing with plays that have promotional activity going on behind the scenes, and this instance is no different.

Facebook, Inc. FB Options

FB has recently been pushing its 52-week highs (Hit 42.26 on Friday), so we are looking at how to capitalize on the trend via options trading. The 09/13 $41 Calls (closed at 1.57 yesterday) are of great interest to us, because if FB can breakout to $45 by next Friday, we could be looking at multi-bag gains from these contracts.

Extended Watchlist:
RMTI, INO, ZLCS, CYTK, STXS

GRPR, BRND & Extended Watchlist

Grid Petroleum Corp. GRPR
GRPR has behaved exactly as we hoped it would this week. We alerted the stock as a momentum play in Wednesday’s extended watchlist, at which time it was trading as low as .0013. It broke a key resistance point at .0016 and closed at .0017. This led us to include it in it in yesterday morning’s pre-market report. The stock would go on to see a high of .0029 on 12X the 3mo. average volume, marking a 123% in just two days time.

With the kind of volume we saw in GRPR yesterday, it still qualifies as a momentum play, so we’ll be monitoring the situation closely during today’s trading.

Premier Brands, Inc. BRND
BRND made a massive move for us when we first put it on our watchlist on July 10th. After a recent consolidation following that big run, yesterday we saw the stock make a nice bounce off of the 50DMA. If it can break above the penny–mark, we like BRND’s chances of providing us with some additional gains.

Side Note:
AAPL $455 Calls have provided several daytrading opportunities this week, and there’s a good chance that we see the volatility continue today. They closed at $2.96 yesterday.

LNKD dropped their earnings after the close yesterday, and this morning the stock is gapping up, so we’ll be looking at in-the-money Calls at $225 and $230.

Extended Watchlist:
ALSK, ZLCS, RENN, BIOD, SORL,

FOLD, MWIP & Extended Watchlist

FOLD caught our attention yesterday as an intriguing pharmaceutical play that recently underwent some panic selling, and is now coming off of the resultant bottom.First a little back-story: Amicus has been teamed up with pharma giant, GlaxoSmithKline (GSK), running clinical trials on a drug called migalastat HCI, meant to treat a rare disease in which a genetic mutation prevents enzymes from breaking down a fatty substance referred to as GL-3. As a result, GL-3 build up in the kidneys can lead to organ failure and death.

The big sell-off occurred back in late December when the duo announced that the study, statistically, failed to meet their objectives after a 6 month period, making a fast-track to FDA approval an impossibility.

The encouraging news, and the reason we think now is a prime time to take a look at FOLD, is that the studies do not conclude at the 6 month point; they have continued, and the 12 month results are expected to come early in 2013. While failing to meet project goals, there was still a 50% reduction in GL-3 buildup in 41% of the migalastat HCI group, as compared to just 28% of the placebo group. The 12-month results will be accompanied by the company meeting FDA officials to discuss the track to approval, and how it is altered by the results of trials still underway.

John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT. which can be viewed via a LIVE WEBCAST on the specified date and time.

What really jumps out to us, is simply the fact that FOLD recently saw a big gap down, and has now begun to recover. Often in the past we’ve seen cases such as this where the stock bounces back to fill the gap, offering up great opportunities for gain.

It could also come to that sooner, rather than later- The company also has other irons in the fire, as this morning it released a PR regarding another of its drugs currently in testing phases, this time with positive results:


Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

CRANBURY, N.J., Jan 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease.

___

We will be continuing to follow this play, and keep everyone updated as more details arise.

___

MediSwipe, Inc. MWIP

A lot of you may have missed our last report before the holidays, in which we mentioned that we would like to see MWIP continue to hold support above a penny and test its previous highs. Yesterday saw the stock break past its previous high of .0199 into blue-sky territory, hitting a high of .0289, earning us a spot on the Penny Stock Rumble with a gain of 50%

In total, from the low following our first mention of MWIP back at .0024, yesterday’s high marks an astonishing 1104% gain.

If and when we see a pullback on MWIP, we want to see the previous resistance of .0199 hold as a future level of support for us to remain bullish.

___

Extended Watchlist:

UNLA, AHFD, AXCG, SAPX, SFAZ, ZLCS